PRX was a company i followed over the past few years. A generic drug company, that i think one day will trade north of $50. During a presentation today, they noted higher margins and possible upside revisions to guidance. I think this stock is currently undervalued, and should see $40 in short order.
The company sees 2012-2014 CAGR for revenue of 8%; sees CAGR for cash EPS of 15%. The company says potential opportunities for upside to its three-year guidance exist, including new AG partnerships, potential acquisitions, less erosion of base generics than expected, and better pipeline production. Information taken from investor day slide presentation.
Chat Room members were alerted to the $35 Jan 21st calls @ .35.
Lets see if we get some breakout volume as the stock is currently above the Moving averages and upper bollinger band.